Humana Stock Rockets 21% as Momentum Builds With 5-Day Streak
Humana (HUM) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 21% return. The company has gained about $7.5 Bil in value over the last 5 days, with its current market capitalization at about $36 Bil. The stock remains 18.7% above its value at the end of 2024. This compares with year-to-date returns of 14.8% for the S&P 500.
HUM provides medical benefit plans through Retail, Group and Specialty, and Healthcare Services segments, serving approximately 17 million members as of December 31, 2021. After this rally, is HUM still a buy – or is it time to lock in gains? Deep dive with Buy or Sell HUM.
HUM stock has jumped meaningfully recently and we currently find it attractive. While this may feel like an opportunity, there is significant risk in relying on a single stock. On the other hand, there is a huge value to a broader diversified approach. If you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio (HQ) – HQ has outperformed its benchmark – a combination of S&P 500, Russell, and S&P midcap index, and achieved returns exceeding 91% since its inception. Risk management is key – consider, what could long-term portfolio performance be if you blended 10% commodities, 10% gold, and 2% crypto with HQ’s performance metrics.
Comparing HUM Stock Returns With The S&P 500
The following table summarizes the return for HUM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | HUM | S&P 500 |
|---|---|---|
| 1D | 0.9% | 0.6% |
| 5D (Current Streak) | 20.8% | 0.6% |
| 1M (21D) | 9.5% | 3.7% |
| 3M (63D) | 28.8% | 7.5% |
| YTD 2025 | 18.7% | 14.8% |
| 2024 | -44.0% | 23.3% |
| 2023 | -9.9% | 24.2% |
| 2022 | 11.2% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has HUM behaved after prior drops? See HUM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 51 S&P constituents with 3 days or more of consecutive gains and 78 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 45 |
| 4D | 15 | 19 |
| 5D | 9 | 7 |
| 6D | 2 | 2 |
| 7D or more | 4 | 5 |
| Total >=3 D | 51 | 78 |
Key Financials for Humana (HUM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $106.4 Bil | $117.8 Bil |
| EBT | $3.4 Bil | $1.7 Bil |
| Net Income | $2.5 Bil | $1.2 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $32.1 Bil | $32.4 Bil |
| EBT | $1.7 Bil | $741.0 Mil |
| Net Income | $1.2 Bil | $545.0 Mil |
While HUM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.